This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Check-in on prescribing pattern on Cibinqo treating atopic dermatitis
Ticker(s): PFEWho's the expert?
Institution: University of British of Columbia
- Head of the Department of Dermatologic Oncology at the British Columbia Cancer Agency
- Clinical and research interests include dermatologic therapeutics and oncology
- Has conducted over 60 studies, published extensively: over 80 journal publications, 60 papers presented at conferences, and 11 chapters co-authored in textbooks
- Manages 20 patients with Alopecia Areata
- Plans on prescribing Olumiant
Interview GoalDiscussing the standard of care and general prescribing pattern of CIBINQO™ (abrocitinib), a Janus kinase (JAK) inhibitor indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
